Press Releases

Epic Sciences Expands Partnership with LabCorp to Provide Circulating Tumor Cell Analysis and Support Oncology Clinical Trials in Asia

Epic Sciences Expands Silicon Valley Bank Credit Facility

Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity

Epic Sciences to Present at UBS Global Healthcare Conference

Epic Sciences Demonstrates Single Cell Genetic Analysis for Circulating Tumor Cells

Epic Sciences and The Prostate Cancer Clinical Trials Consortium Collaborate to Advance Therapeutic Development

Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference

Epic Sciences Appoints Chris Bernard as Chief Commercial Officer

Epic Sciences Announces Presentation of Three Studies on Novel CTC Liquid Biopsy Assays for Metastatic Prostate Cancers and Bladder Cancers at 2015 ASCO GU Cancer Symposium

Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers

Epic Sciences Receives CLIA Certification for its Cancer Diagnostics Laboratory

Epic Sciences to Present at the Piper Jaffray Healthcare Conference

Epic Sciences to Present Data on a Combination CTC and cfDNA Assay for Molecular Targets of Non-Small Cell Lung Cancer Therapies at the 26th EORTC-NCI-AACR Symposium

An assay to detect clinically actionable non-small cell lung cancer (NSCLC) biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood will be described at EORTC-NCI-AACR Symposium.

Epic Sciences Appoints Toni Wayne as Vice President of Human Resources

Epic Sciences to Present on Characterizing PD-L1 in Circulating Tumor Cells of Non-Small Cell Lung Cancer Patients at the 26th EORTC-NCI-AACR Symposium

PD-L1 protein expression in circulating tumor cells (CTCs) in a liquid biopsy from non-small cell lung cancer (NSCLC) patients — data will be presented at EORTC.

Epic Sciences Appoints Glen Freiberg as Vice President of Regulatory Affairs and Quality Assurance

Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors

Epic Sciences Selected to Present at Cavendish Global Health Impact Forum

Epic Sciences Appoints Pascal Bamford, Ph.D. as Vice President of Product Development

Epic Sciences Partners with LabCorp to Accelerate European Clinical Sample Processing for CTC Technology

Epic Sciences and Collaborators to Present Six Novel Abstracts at ASCO GU Addressing the Clinical Applicability of Epic's CTC Technology in Prostate Cancer

Epic Sciences Appoints Michael Rodriguez as Chief Financial Officer

Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO

Epic Sciences' Research in Prostate Cancer Presented at the 2013 ASCO Genitourinary Cancers Symposium

Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test

Epic Sciences Announces Series B Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Epic Sciences Announces Six Pharma Circulating Tumor Cell Collaborations